Clinical Trial Update: Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of pegylated interferon α-2b with ruxolitinib for hydroxyurea-resistant or intolerant polycythemia vera; recruitment is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Drugs mentioned

• Pegylated Interferon α-2b (pegylated interferon alfa-2b)
• Ruxolitinib (Jakafi) (ruxolitinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Polycythemia Vera | Phase 2 | Status: RECRUITING